Cargando…

Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)

BACKGROUND: Non-small-cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations may exhibit primary resistance to EGFR tyrosine kinase inhibitor (TKI). We aimed to examine genomic alterations associated with de novo resistance to gefitinib in a prospective s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lim, Sun Min, Kim, Hye Ryun, Cho, Eun Kyung, Min, Young Joo, Ahn, Jin Seok, Ahn, Myung-Ju, Park, Keunchil, Cho, Byoung Chul, Lee, Ji-Hyun, Jeong, Hye Cheol, Kim, Eun Kyung, Kim, Joo-Hang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095002/ https://www.ncbi.nlm.nih.gov/pubmed/27121209 http://dx.doi.org/10.18632/oncotarget.8904

Ejemplares similares

Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)
por: Lee, Ji Yun, et al.
Publicado: (2016)

Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01)
por: Ku, Bo Mi, et al.
Publicado: (2018)

Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing
por: Chun, You Jin, et al.
Publicado: (2019)

An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations
por: Park, Keunchil, et al.
Publicado: (2021)

Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer
por: Hong, Min Hee, et al.
Publicado: (2019)

Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial
por: Kang, Jin Hyoung, et al.
Publicado: (2016)

A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
por: Yoo, Kwai Han, et al.
Publicado: (2019)

Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study
por: Ahn, Beung-Chul, et al.
Publicado: (2021)

Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study
por: Lee, Ji Hyun, et al.
Publicado: (2016)

Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers
por: Ahn, Jin Woo, et al.
Publicado: (2014)

Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer
por: Lee, Jiyun, et al.
Publicado: (2019)

Endobronchial ultrasound‐guided re‐biopsy of non–small cell lung cancer with acquired resistance after EGFR tyrosine kinase inhibitor treatment
por: Hong, Kyung Soo, et al.
Publicado: (2022)

Transglutaminase 2 Expression Predicts Progression Free Survival in Non-Small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Jeong, Jae-Heon, et al.
Publicado: (2013)

Alteration status and prognostic value of MET in head and neck squamous cell carcinoma
por: Cho, Yoon Ah, et al.
Publicado: (2016)

Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Ahn, Beung-Chul, et al.
Publicado: (2021)

The Impact of Cigarette Smoking on the Frequency of and Qualitative Differences in KRAS Mutations in Korean Patients with Lung Adenocarcinoma
por: Kim, Hye Ryun, et al.
Publicado: (2013)

The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges
por: Sang, Yun Beom, et al.
Publicado: (2022)

Dietary Patterns and Osteoporosis Risk in Postmenopausal Korean Women
por: Park, Seon-Joo, et al.
Publicado: (2012)

A Pilot Study of Trans-Arterial Injection of (166)Holmium-Chitosan Complex for Treatment of Small Hepatocellular Carcinoma
por: Cho, Byoung Chul, et al.
Publicado: (2005)

Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer
por: Ji, Wonjun, et al.
Publicado: (2013)

Real World Characteristics and Clinical Outcomes of HER2-Mutant Non–Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing
por: Ahn, Beung-Chul, et al.
Publicado: (2023)

Validation of the Korean version of the European Community Respiratory Health Survey screening questionnaire for use in epidemiologic studies for adult asthma
por: Song, Woo-Jung, et al.
Publicado: (2015)

Analysis of facial vascular pattern characteristics in the Korean population
por: Kim, Tae‐Eun, et al.
Publicado: (2023)

Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients
por: Cho, Byoung Chul, et al.
Publicado: (2008)

Religious Affiliations and Clinical Outcomes in Korean Patients With Acute Myocardial Infarction
por: Oh, Seok, et al.
Publicado: (2022)

A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)
por: Kim, Hye Ryun, et al.
Publicado: (2016)

Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)
por: Kim, Hye Ryun, et al.
Publicado: (2017)

Association between Living Arrangements and Influenza Vaccination Rates among Elderly South Korean People: The Fifth Korea National Health and Nutrition Examination Survey (KNHANES V-2)
por: Cho, Hye Min, et al.
Publicado: (2015)

Predictors of In-Hospital Mortality in Korean Patients with Acute Myocardial Infarction
por: Yang, Hae Young, et al.
Publicado: (2019)

Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22
por: Jung, Hyun Ae, et al.
Publicado: (2022)

Altered expression of cellular proliferation, apoptosis and the cell cycle-related genes in lung cancer cells with acquired resistance to EGFR tyrosine kinase inhibitors
por: Lee, Tae-Gul, et al.
Publicado: (2017)

The incidence and etiology of sixth cranial nerve palsy in Koreans: A 10-year nationwide cohort study
por: Jung, Eun Hye, et al.
Publicado: (2019)

Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors
por: Kim, Hongsik, et al.
Publicado: (2021)

A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
por: Lee, Ji Hyun, et al.
Publicado: (2021)

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
por: Kim, Youjin, et al.
Publicado: (2019)

Impact of P2Y12 inhibitors on cardiovascular outcomes of Korean acute myocardial infarction patients with baseline thrombocytopenia
por: Oh, Seok, et al.
Publicado: (2022)

Utility of the Rio Score and Modified Rio Score in Korean Patients with Multiple Sclerosis
por: Hyun, Jae-Won, et al.
Publicado: (2015)

Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies
por: Jang, Seong Bok, et al.
Publicado: (2021)

Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer
por: Park, Silvia, et al.
Publicado: (2015)

Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus
por: Lim, Sun Min, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_8e9gdvemj0jaukmthr9qb6idu8